. 2013 Apr 24;56(10):3852–3865. doi: 10.1021/jm400348g

Table 4. Human β₁- and β₂-Adrenoceptor Binding Affinity and Receptor Selectivity of 1-(2-(3-(4-(2-(Alkyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-((4-hydroxy)phenyl)ureas 28a–c^a.

compd	R₁	log K_D β₁	n	log K_D β₂	n	selectivity ratio (β₁/β₂)
19		–7.49 ± 0.03	11	^b	11
29a	cyclopentyl	–8.13 ± 0.05	12	–5.45 ± 0.07	7	478
29b	p-FC₆H₄CH₂CH₂	–8.50 ± 0.05	9	–5.91 ± 0.05	9	389
29c	CH₃CH₂	–7.04 ± 0.04	16	^b	16

Values represent the mean ± SEM of n separate experiments. Log K_D values were obtained from ³H-CGP 12177 whole cell binding studies in CHO cells stably expressing the human β₁- or β₂-adrenoceptors.

Incomplete inhibition of specific ³H-CGP12177 binding meant that generation of an affinity value (log K_D value) by this method was not possible.

Table 4. Human β1- and β2-Adrenoceptor Binding Affinity and Receptor Selectivity of 1-(2-(3-(4-(2-(Alkyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-((4-hydroxy)phenyl)ureas 28a–ca.

Table 4. Human β₁- and β₂-Adrenoceptor Binding Affinity and Receptor Selectivity of 1-(2-(3-(4-(2-(Alkyloxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-((4-hydroxy)phenyl)ureas 28a–c^a.